Search research articles
Contact Us
Filters
Showing results (991-1000 of 1,012) with videos related to
Page
of 102
Sort By:
JAMA Dermatology
|
March 7, 2019
Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10
Megan H Noe, Misha Rosenbach, Rebecca A Hubbard, et al.
The Lancet. HIV
|
March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
Emma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
The Lancet. Haematology
|
January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
International Journal of Epidemiology
|
April 11, 2015
CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa
Elvin H Geng, Torsten B Neilands, Rodolphe Thièbaut, et al.
The Lancet. Haematology
|
May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Nature Cancer
|
March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Sean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
American Journal of Epidemiology
|
April 9, 2025
Defining methodologic and other core competencies for PhD-level training in epidemiology
Hailey R Banack, Laura C Rosella, Stephanie Shiau, et al.
Blood
|
October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
Pietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
Page
of 102
Search research articles
Search
Showing results (991-1000 of 1,012) with videos related to
Sort By:
Page
of 102
JAMA Dermatology
|
March 7, 2019
Development and Validation of a Risk Prediction Model for In-Hospital Mortality Among Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis-ABCD-10
Megan H Noe, Misha Rosenbach, Rebecca A Hubbard, et al.
The Lancet. HIV
|
March 30, 2026
Risk of obesity, diabetes, hypertension, and major adverse cardiovascular events after a switch to an integrase inhibitor: a target trial emulation in REPRIEVE
Emma M Kileel, Carlos D Malvestutto, Markella V Zanni, et al.
The Lancet. Haematology
|
January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trial
Andrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
International Journal of Epidemiology
|
April 11, 2015
CD41 T cell recovery during suppression of HIV replication: an international comparison of the immunological efficacy of antiretroviral therapy in North America, Asia and Africa
Elvin H Geng, Torsten B Neilands, Rodolphe Thièbaut, et al.
The Lancet. Haematology
|
May 3, 2016
Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial
Andrés J M Ferreri, Kate Cwynarski, Elisa Pulczynski, et al.
Nature Cancer
|
March 25, 2022
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Sean H Lim, Beth Stuart, Debora Joseph-Pietras, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 11, 2026
High-Dose Methotrexate as CNS Prophylaxis in Ultra High-Risk Large B-Cell Lymphoma: An International Multicenter Analysis
Matthew R Wilson, Katharine L Lewis, Amy A Kirkwood, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 21, 2019
Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice
Lindsey E Roeker, Christopher P Fox, Toby A Eyre, et al.
American Journal of Epidemiology
|
April 9, 2025
Defining methodologic and other core competencies for PhD-level training in epidemiology
Hailey R Banack, Laura C Rosella, Stephanie Shiau, et al.
Blood
|
October 13, 2023
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma
Pietro R Di Ciaccio, Mark N Polizzotto, Kate Cwynarski, et al.
Page
of 102